David E. Heppner

Roswell Park Comprehensive Cancer Center

Also affiliated with Jacobs (United States), University at Buffalo, State University of New York

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 34 papers. Top paper: “A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging”.

A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging

Cell(2020)10.1016/j.cell.2020.02.012

N/A

0DataRank · unranked

420 citations

Mark P. Jedrychowski, Devin K. Schweppe, Edward L. Huttlin, Qing Yu, David E. Heppner +15 more

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

(2020)10.26434/chemrxiv.13416452.v1

N/A

0DataRank · unranked

0 citations

David E. Heppner, Ciric To, Marcel C. Guenther, Bo Hee Shin, Jaimin K Rana +6 more

Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00848

N/A

0DataRank · unranked

43 citations

David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana +13 more

A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer

Protein Science(2021)10.1002/pro.4125

N/A

0DataRank · unranked

33 citations

Michael J. Eck, David E. Heppner

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Nature Cancer(2022)10.1038/s43018-022-00351-8

N/A

0DataRank · unranked

163 citations

Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala +21 more

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-30258-y

N/A

0DataRank · unranked

86 citations

Ciric To, David E. Heppner, Jaimin K. Rana, Anna M. Schmoker, Jaebong Jang +7 more

Architecture of the NADPH oxidase family of enzymes

Redox Biology(2022)10.1016/j.redox.2022.102298

N/A

0DataRank · unranked

76 citations

Uriy V. Grabovyy, Aniket Maini, Scott Scouten, Albert van der Vliet, Andrea Mattevi +2 more

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-33210-2

N/A

0DataRank · unranked

28 citations

Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung +18 more

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC

Bioorganic & Medicinal Chemistry Letters(2022)10.1016/j.bmcl.2022.128718

N/A

0DataRank · unranked

23 citations

David E. Heppner, Tyler S. Beyett, Ciric To, Seth C. Azevedo, Jaebong Jang +11 more

Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.27.505540

N/A

0DataRank · unranked

5 citations

Jaimin K. Rana, Ilse K. Schaeffner, David E. Heppner, Michael J. Eck, Tyler S. Beyett

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5-v2

N/A

0DataRank · unranked

3 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5

N/A

0DataRank · unranked

0 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor

Cell chemical biology(2023)10.1016/j.chembiol.2023.09.013

N/A

0DataRank · unranked

24 citations

Jaweria Bakar, Surbhi P. Chitnis, Erin L. Sausville, Kumar Dilip Ashtekar, Brianna E. Mendelson +5 more

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors

Methods in enzymology on CD-ROM/Methods in enzymology(2023)10.1016/bs.mie.2023.03.013

N/A

0DataRank · unranked

8 citations

Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan Laufer, David E. Heppner +1 more

Development of Mutant-Selective Allosteric EGFR Inhibitors for Drug-Resistant Lung Cancer

Journal of Pharmacology and Experimental Therapeutics(2023)10.1124/jpet.122.162040

N/A

0DataRank · unranked

1 citations

Ciric To, David E. Heppner, Thomas W. Gero, Nathanael S. Gray, David A. Scott +3 more

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology

Molecular Pharmacology(2023)10.1124/molpharm.123.000768

N/A

0DataRank · unranked

2 citations

Ilse K. Schaeffner, David E. Heppner, Ciric To, Pasi A. Jänne, Tyler S. Beyett +2 more

Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Calvin D. Pham, Ilse K. Schaeffner, Surbhi P. Chitnis, Tahereh Damghani +12 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn-v2

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-tkqqk

N/A

0DataRank · unranked

2 citations

Daniel A. Urul, Blessing C. Ogboo, Florian Wittlinger, Stefan Laufer, Erik Schaefer +3 more

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-zzfc3

N/A

0DataRank · unranked

2 citations

Surbhi P. Chitnis, Calvin D Pham, Tahereh Damghani, Ilse K. Schaeffner, Matthew Q. Deng +13 more

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.

ChemRxiv(2023)10.26434/chemrxiv-2023-v522v

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan Laufer, David E. Heppner +1 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Research Square(2023)10.21203/rs.3.rs-3286949/v1

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin Pham +15 more

Design and development of mutant EGFR inhibitors from a structural perspective

Indian Journal of Biochemistry and Biophysics(2023)10.56042/ijbb.v60i9.3967

N/A

0DataRank · unranked

0 citations

David E. Heppner

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Communications Chemistry(2024)10.1038/s42004-024-01108-3

N/A

0DataRank · unranked

24 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase

ChemMedChem(2024)10.1002/cmdc.202300343

N/A

0DataRank · unranked

10 citations

Jaimin K. Rana, Ilse K. Schaeffner, David E. Heppner, Michael J. Eck, Tyler S. Beyett

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c02311

N/A

0DataRank · unranked

8 citations

Surbhi P. Chitnis, Calvin D. Pham, Tahereh Damghani, Kishan B. Patel, Mareike Möllers +17 more

Twelve CO molecules for the price of one. A simple water-soluble organometallic CORM, [Mn(CO)3(µ3-OH)]4

Polyhedron(2024)10.1016/j.poly.2024.116859

N/A

0DataRank · unranked

2 citations

David E. Heppner, Brian Buckley, Justin Griffiths, Parami S. Gunasekera, Jully Patel +6 more

Demystifying Functional Parameters for Irreversible Enzyme Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c01721

N/A

0DataRank · unranked

44 citations

Blessing C. Ogboo, Daniel A. Urul, Earl W. May, Erik Schaefer, Andrew S. Murkin +2 more

Lazertinib: breaking the mold of third-generation EGFR inhibitors

RSC Medicinal Chemistry(2025)10.1039/d4md00800f

N/A

0DataRank · unranked

16 citations

David E. Heppner, Kishan B. Patel

Structure–Activity Relationships of Inactive‐Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets

Archiv der Pharmazie(2025)10.1002/ardp.70027

N/A

0DataRank · unranked

5 citations

Florian Wittlinger, Mareike Möllers, Tyler J. Hartman, Marcel Günther, Michael J. Eck +3 more

Enhancing Selectivity and Potency of SNAr Covalent Inhibitors of NADPH Oxidase Enzymes

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c01272

N/A

0DataRank · unranked

3 citations

Kishan B. Patel, Marta Massari, Sara Marchese, Joana Reis, Emily Joyce +8 more

Ascertaining a Structural Basis in Drug Discovery and Development

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c00326

N/A

0DataRank · unranked

4 citations

David E. Heppner

Structure-activity relationships of inactive-conformation binding EGFR inhibitors: Linking the ATP and allosteric pockets

ChemRxiv(2025)10.26434/chemrxiv-2025-2cdjb

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Mareike Möllers, Tyler J. Hartman, Marcel Günther, Michael J. Eck +3 more

Proposed Cuts to Health Research Threaten the Future of Drug Discovery and Development

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c02080

N/A

0DataRank · unranked

0 citations

David E. Heppner